Karyopharm Therapeutics Inc. (KPTI)
Largest Insider Buys in Sector
KPTI Stock Price History Chart
KPTI Stock Performance
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with …
Insider Activity of Karyopharm Therapeutics Inc.
Over the last 12 months, insiders at Karyopharm Therapeutics Inc. have bought $0 and sold $1.8M worth of Karyopharm Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Karyopharm Therapeutics Inc. have bought $130,090 and sold $3.46M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 41,140 shares for transaction amount of $49,985 was made by BOHLIN GAREN G (director) on 2023‑09‑12.
List of Insider Buy and Sell Transactions, Karyopharm Therapeutics Inc.
| 2024-12-04 | Sale | President and CEO | 3,620 0.003% | $0.81 | $2,932 | -8.60% | ||
| 2024-11-05 | Sale | President and CEO | 3,675 0.0029% | $0.91 | $3,346 | -3.32% | ||
| 2024-10-04 | Sale | President and CEO | 3,607 0.0036% | $0.88 | $3,172 | -4.77% | ||
| 2024-09-04 | Sale | President and CEO | 3,667 0.003% | $0.72 | $2,647 | +16.46% | ||
| 2024-09-04 | Sale | EVP & Chief Commercial Officer | 5,356 0.0044% | $0.72 | $3,866 | +16.46% | ||
| 2024-09-04 | Sale | EVP, CFO & Treasurer | 7,050 0.0057% | $0.72 | $5,089 | +16.46% | ||
| 2024-09-04 | Sale | SVP, General Counsel&Secretary | 3,971 0.0032% | $0.72 | $2,866 | +16.46% | ||
| 2024-08-06 | Sale | President and CEO | 3,608 0.0032% | $0.93 | $3,355 | -3.43% | ||
| 2024-07-30 | Sale | EVP, Chief Development Officer | 2,883 0.0023% | $1.06 | $3,056 | -12.86% | ||
| 2024-07-05 | Sale | President and CEO | 3,616 0.0025% | $0.85 | $3,077 | 0.00% | ||
| 2024-06-07 | Sale | director | 2,240 0.0018% | $0.95 | $2,130 | -12.50% | ||
| 2024-06-06 | Sale | director | 118,452 0.096% | $0.98 | $116,415 | -13.50% | ||
| 2024-06-05 | Sale | director | 468,044 0.3619% | $0.96 | $448,480 | -15.23% | ||
| 2024-06-04 | Sale | President and CEO | 3,592 0.0033% | $0.99 | $3,556 | -9.02% | ||
| 2024-06-04 | Sale | EVP, CFO & Treasurer | 652 0.0006% | $0.99 | $645 | -9.02% | ||
| 2024-06-04 | Sale | director | 341,040 0.2976% | $0.95 | $324,704 | -9.02% | ||
| 2024-06-03 | Sale | director | 360,744 0.3105% | $1.00 | $360,997 | -13.68% | ||
| 2024-05-31 | Sale | director | 204,394 0.1709% | $0.95 | $194,992 | -12.02% | ||
| 2024-05-06 | Sale | President and CEO | 3,576 0.003% | $1.13 | $4,041 | -25.40% | ||
| 2024-04-22 | Sale | EVP & Chief Medical Officer | 6,789 0.006% | $1.17 | $7,943 | -22.71% |
Insider Historical Profitability
| PAKIANATHAN DEEPIKA | director | 0 0% | $0.64 | 5 | 7 | +36.66% |
| Frenkel Ran | EVP, Chief Dev. Officer | 168290 0.1334% | $0.64 | 2 | 9 | <0.0001% |
| Shah Jatin | EVP, Chief Medical Officer | 129450 0.1026% | $0.64 | 1 | 6 | <0.0001% |
| Brannelly Paul | SVP, FINANCE & ADMIN, TREAS | 66136 0.0524% | $0.64 | 3 | 0 | +28.23% |
| BOHLIN GAREN G | director | 45140 0.0358% | $0.64 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $14.27M | 8.03 | 9.45M | -6.2% | -$942,238.50 | <0.0001 | |
| The Vanguard Group | $12.59M | 7.08 | 8.34M | -4.27% | -$561,353.09 | <0.0001 | |
| Avidity Partners Management Lp | $12.53M | 7.05 | 8.3M | 0% | +$0 | 0.48 | |
| Palo Alto Investors Lp | $7.7M | 4.34 | 5.1M | 0% | +$0 | 0.87 | |
| Eversept Partners LP | $7.57M | 4.26 | 5.02M | New | +$7.57M | 0.58 |